- Conditions
- Respiratory Distress Syndrome, Newborn
- Interventions
- CHF5633, Poractant alfa
- Drug
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Industry
- Eligibility
- 1 Hour to 24 Hours
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 23
- States / cities
- Mobile, Alabama • Los Angeles, California • Orange, California + 20 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Respiratory Distress Syndrome
- Interventions
- Nasal continuous positive airway pressure (nCPAP), Laryngeal Mask Airway (LMA) to deliver surfactant, Surfactants, Pulmonary
- Device · Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- Up to 36 Hours
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 7
- States / cities
- Loma Linda, California • San Diego, California • Maple Grove, Minnesota + 4 more
- Conditions
- Acute Respiratory Distress Syndrome
- Interventions
- CUROSURF® (poractant alfa)
- Drug
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Respiratory Distress Syndrome (RDS)
- Interventions
- LISA combination product (Curosurf+catheter CHF6440), Curosurf through conventional administration (endotracheal tube)
- Combination Product · Drug
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Industry
- Eligibility
- 30 Minutes to 24 Hours
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 26
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 22 more
- Conditions
- Respiratory Distress Syndrome
- Interventions
- Curosurf®, Survanta®
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 15 Minutes to 12 Hours
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan